Cargando…

COVID-19 in Europe: from outbreak to vaccination

BACKGROUND: COVID-19 is a pandemic of unprecedented proportions in recent human history. To date, the world has paid a high toll in terms of human lives lost, and on economic, financial, and social repercussions. In Europe, countries tried to mobilize all resources available to contain the COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Vicente, Paula, Suleman, Abdul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716177/
https://www.ncbi.nlm.nih.gov/pubmed/36461031
http://dx.doi.org/10.1186/s12889-022-14454-5
_version_ 1784842627067150336
author Vicente, Paula
Suleman, Abdul
author_facet Vicente, Paula
Suleman, Abdul
author_sort Vicente, Paula
collection PubMed
description BACKGROUND: COVID-19 is a pandemic of unprecedented proportions in recent human history. To date, the world has paid a high toll in terms of human lives lost, and on economic, financial, and social repercussions. In Europe, countries tried to mobilize all resources available to contain the COVID-19 effects, but the outcomes are diverse across countries. There have also been massive efforts geared towards finding safe and effective vaccines and to distribute them massively to the population. The main objective of this paper is to describe the COVID-19 prevalence in Europe. Secondly, it aims to identify epidemiological typologies allowing to distinguish the countries in terms of their response to the pandemic, and finally assess the effect of vaccination on pandemic control. METHODS: The study covers 30 European countries: EU 27 in addition to Norway, Switzerland, and United Kingdom. Four epidemiological variables are analyzed at two distinct moments, at the end of 2020 and at the beginning of 2022: total number of cases per million, total number of deaths per million, total number of tests per thousand, and case fatality rate. In a second step, it uses a fuzzy approach, namely archetypal analysis, to identify epidemiological typologies, and positions countries by their response to the pandemic. Finally, it assesses how vaccination, stringency measures, booster doses and population age affect the case fatality rate, using a multiple regression model. RESULTS: The outcomes unveil four epidemiological typologies for both periods. The clearest sign of change in the two periods concerns the case fatality rate that is found to be low in a single typology in 2020 but occurs in three typologies in 2022, although to different degrees. There is also statistical evidence of the positive impact of the primary vaccination on mortality reduction; however, the same does not hold for the booster dose and stringency measures. CONCLUSIONS: The study shows that primary vaccination is the most effective measure to reduce mortality by COVID-19 suggesting that vaccination provides hope for an end to the pandemic. However, a worldwide access to vaccination is needed to make this happen. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-14454-5.
format Online
Article
Text
id pubmed-9716177
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97161772022-12-02 COVID-19 in Europe: from outbreak to vaccination Vicente, Paula Suleman, Abdul BMC Public Health Research BACKGROUND: COVID-19 is a pandemic of unprecedented proportions in recent human history. To date, the world has paid a high toll in terms of human lives lost, and on economic, financial, and social repercussions. In Europe, countries tried to mobilize all resources available to contain the COVID-19 effects, but the outcomes are diverse across countries. There have also been massive efforts geared towards finding safe and effective vaccines and to distribute them massively to the population. The main objective of this paper is to describe the COVID-19 prevalence in Europe. Secondly, it aims to identify epidemiological typologies allowing to distinguish the countries in terms of their response to the pandemic, and finally assess the effect of vaccination on pandemic control. METHODS: The study covers 30 European countries: EU 27 in addition to Norway, Switzerland, and United Kingdom. Four epidemiological variables are analyzed at two distinct moments, at the end of 2020 and at the beginning of 2022: total number of cases per million, total number of deaths per million, total number of tests per thousand, and case fatality rate. In a second step, it uses a fuzzy approach, namely archetypal analysis, to identify epidemiological typologies, and positions countries by their response to the pandemic. Finally, it assesses how vaccination, stringency measures, booster doses and population age affect the case fatality rate, using a multiple regression model. RESULTS: The outcomes unveil four epidemiological typologies for both periods. The clearest sign of change in the two periods concerns the case fatality rate that is found to be low in a single typology in 2020 but occurs in three typologies in 2022, although to different degrees. There is also statistical evidence of the positive impact of the primary vaccination on mortality reduction; however, the same does not hold for the booster dose and stringency measures. CONCLUSIONS: The study shows that primary vaccination is the most effective measure to reduce mortality by COVID-19 suggesting that vaccination provides hope for an end to the pandemic. However, a worldwide access to vaccination is needed to make this happen. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-14454-5. BioMed Central 2022-12-02 /pmc/articles/PMC9716177/ /pubmed/36461031 http://dx.doi.org/10.1186/s12889-022-14454-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Vicente, Paula
Suleman, Abdul
COVID-19 in Europe: from outbreak to vaccination
title COVID-19 in Europe: from outbreak to vaccination
title_full COVID-19 in Europe: from outbreak to vaccination
title_fullStr COVID-19 in Europe: from outbreak to vaccination
title_full_unstemmed COVID-19 in Europe: from outbreak to vaccination
title_short COVID-19 in Europe: from outbreak to vaccination
title_sort covid-19 in europe: from outbreak to vaccination
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716177/
https://www.ncbi.nlm.nih.gov/pubmed/36461031
http://dx.doi.org/10.1186/s12889-022-14454-5
work_keys_str_mv AT vicentepaula covid19ineuropefromoutbreaktovaccination
AT sulemanabdul covid19ineuropefromoutbreaktovaccination